Healthstream (HSTM) Research & Development (2010 - 2026)

Healthstream (HSTM) has 17 years of Research & Development data on file, last reported at $13.6 million in Q1 2026.

• Research & Development for Q1 2026 came in at $13.6 million, up 12.94% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.5 million (up 7.44% YoY), and the FY2025 annual result was $51.0 million, up 4.28% from the prior year.
• Research & Development retreated to $13.6 million in Q1 2026 per HSTM's latest filing, from $14.8 million in the prior quarter.
• Over five years, Research & Development peaked at $14.8 million in Q4 2025 and troughed at $10.4 million in Q1 2022.
• A 5-year average of $12.0 million and a median of $12.0 million in 2024 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development slipped 5.01% in 2023, then advanced 16.35% in 2025.
• A 5-year view of Research & Development shows it stood at $11.8 million in 2022, then rose by 1.04% to $11.9 million in 2023, then gained by 6.3% to $12.7 million in 2024, then increased by 16.35% to $14.8 million in 2025, then retreated by 7.79% to $13.6 million in 2026.
• Business Quant data shows HSTM's Research & Development at $13.6 million in Q1 2026, $14.8 million in Q4 2025, and $12.1 million in Q3 2025.